Mårten Winge M.Sc., Chief Executive Officer
During the past twenty years, Mårten Winge has held executive management and board positions in a number of biotech companies within the life sciences including Pyrosequencing, Olink, Halo Genomics and Proxeon. He has extensive experience of international marketing, business development and commercialization of new technologies, primarily in start-up and early growth companies. Most recently he was CEO of Cartana AB which was acquired by 10x Genomics. He currently serves on several boards, acts as an advisor to Inossia, and is a business coach for Uppsala Innovation Center. He holds a M.Sc. in Molecular Biology from Karolinska Institute.
Sara Mangsbo, Ph.D., Chief Scientific Officer
Sara Mangsbo, a co-founder of Strike Pharma, has over 15 years of experience in the field of immunotherapy both in the pre-clinical and clinical space. She is Associate Professor and senior lecturer in the Department of Pharmaceutical Biosciences at Uppsala University where she heads a team focused on immuno- oncology studies, specifically to improve immunotherapeutic treatments for solid tumors by developing novel immunotherapeutics and investigating their performance in new model systems.
Tina Furebring, Ph.D., Chief Operations Officer
Tina Furebring brings more than 25 years of experience in early drug development, including extensive experience in the management of preclinical therapeutic candidate projects. Throughout her career she has held senior management and leadership positions, driving both business strategy and the development of individuals and teams. As Senior Vice President at Alligator Biosciences AB, her responsibilities covered projects to generate antibody-based immuno-oncology compounds and development of the company’s technology platform.
Pierre Dönnes Ph.D., Vice President Neoantigen Discovery
Pierre Dönnes, a co-founder of Strike Pharma and currently Vice President Neoantigen Discovery, has focused throughout his academic and industrial career on technology-driven knowledge generation and predictive analytics. He has more than 15 years’ experience in the field of neoantigen discovery development of cancer vaccines, both from academia and industry. He is currently CEO at SciCross AB, a life science company with focus on data analysis in translational medicine and is an honorary professor in the Faculty of Medical Sciences at University College London.